Search
T611
go.drugbank.com/drugs/DB06391ExperimentalT611 is an investigational oral anti-cytomegalovirus (CMV) drug candidate.
Cefamandole
go.drugbank.com/drugs/DB01326ApprovedWithdrawnCefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, [cefamandole nafate].
Etoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawnIt is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile. … Etoperidone is an atypical antidepressant introduced in Europe in 1977.
SF1126
go.drugbank.com/drugs/DB05210InvestigationalSF1126 is an integrin-targeted PI3 kinase inhibitor.
NasoVAX
go.drugbank.com/drugs/DB15859InvestigationalIt is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells[L16313]. … As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230).
Isopropamide
go.drugbank.com/drugs/DB01625ApprovedVet approvedWithdrawnIsopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.
Rolicyclidine
go.drugbank.com/drugs/DB01549ExperimentalIllicitRolicyclidine (PCPy) is classified as a dissociative anesthetic agent. It also has hallucinogenic and sedative properties.
Asunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor.
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[A187316] Triptans abort migraines via action at several serotonin receptors, including 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors, and activity at the 5-HT<sub>1B</sub> receptor has been specifically … [A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class
OPC-14523
go.drugbank.com/drugs/DB05422ExperimentalOPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.